

Publikationer 2003

- Bingefors K, Isacson D, Kristiansen IS. Clinitrac: a novel method for evaluating outcome in Parkinson's disease (abstract). *Value in Health* 2003; 6: 282.
- Bjerrum L, Larsen J, Kragstrup J. Øget forbrug af lipidsænkende lægemidler efter udsendelse af en klinisk vejledning til almen praksis. *Ugeskr Læger* 2003; 165: 1203.
- Bjerrum L, Foged A. Patient information leaflets – helpful guidance or a source of confusion? *Pharmacoepidemiol Drug Saf* 2003; 12: 55-9.
- Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. *Scand J Prim Health Care* 2003; 21: 153-8.
- Bjerrum L, Dessau RB, Hallas J. Recept på nyt antibiotikum efter behandling med sulfamethizol eller pivmecillinam. *Ugeskr Læger* 2003; 165: 3732-5.
- Bjerrum L, Dessau R, Hallas J. Sulfamethizol vs. pivmecillinam til urinvejsinfektion. *Ugeskr Læger* 2003; 165: 4317-8.
- Bro F, Kragstrup J. From black box to complex adaptive system. (Editorial). *Scand J Prim Health Care* 2003; 21: 1.
- Christensen PM, Brøsen K, Brixen K, Andersen M, Kristiansen IS. A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. *Clin Therapeut* 2003; 25: 2575-85.
- Christensen PM, Brixen K, Kristiansen IS. Danish Osteoporosis Outcome Model (DOOM). *Health Economics Papers* 2003:2. Odense: Faculty of Social Sciences, University of Southern Denmark, 2003.
- Foged A, Bjerrum L. Indlægssedler i medicin forvirrer patienterne. *Ugeskr Læger* 2003; 165: 3433.
- Gyrd-Hansen D, Kristiansen IS, Nexøe J, Nielsen JB. How do individuals apply risk information when choosing amongst health care interventions? *Risk Analysis* 2003; 23: 697-704.
- Halvorsen PA, Kristiansen IS, Aasland OG, Førde OH. Medical doctors' perception of the "number needed to treat" (NNT). *Scand J Prim Health Care* 2003; 21: 162-6.
- Hamm L, Mikkelsen B, Kuhr J, Støvring H, Munck A, Kragstrup J. Danish physiotherapists' management of low back pain. *Advances in Physiotherapy* 2003; 5: 109-13.
- Hansen DG, Søndergaard J, Vach W, Gram LF, Rosholm JU, Kragstrup J. Antidepressant drug use in general practice: inter-practice variation and association with practice characteristics. *Eur J Clin Pharmacol* 2003; 59: 143-9.

Hansen CN, Hansen DG, Kragstrup J, Busch O, Munck A. The role of the APO method in improving diabetes care in general practice: the results of a Danish prospective multipractice audit circle. *Quality in Primary Care* 2003; 11: 225-31.

Kristiansen IS, Stavem K, Linnestad K, Pedersen KM. Variasjon i kostnad-effekt-analyser: Hvor presist kan kostnader og nytte ved ny teknologi beregnes? *Tidsskr Nor Lægeforen* 2003; 123: 657-60.

Kristiansen IS, Poulsen PB, Wittrup-Jensen KU. Economic aspects – Saving billions with telemedicine: fact or fiction. I: *Telemedicine and Teledermatology*. (Red.: Burg G). *Curr Probl Dermatol*. Basel: Karger, 2003, vol. 32, p. 63-71.

Kristiansen IS. Competing interests – problem is greater than editorial indicates. (Letter to the editor). *BMJ* 2003; 326: 883.

Kristiansen IS. Competing interests – problem is greater than editorial indicates (letter to the editor). *BMJ* 2003; 326: 883.

Kristiansen IS. Hvor mye bør samfunnet være villig til å betale for helseforbedringer? I: Bringedal B, Iversen T, Kristiansen IS. *Verdien av liv og helse*. HERO Skriftserie 2003: 6. Oslo: Universitetet i Oslo, 2003.

Kristiansen IS. Koronare intervensjoner etter 80-årsalder: Er hjertekirurgi etter 80 år et selvfølgelig behandlingstilbud eller feilslått prioritering? *Tidsskr Nor Lægeforen* 2003; 123: 1735-6.

Kristiansen IS, Christensen PM, Nexøe J. Vurdering af behandlingseffekt ved kroniske sygdomstilstande. Er number-needed-to-treat det bedste effektmål? *Rationel Farmakoterapi* 2003;11.

Kristiansen IS, Nexøe J, Gyrd-Hansen D. Communicating risk at the population level: How useful is the PIN-ER-t? (Rapid Response). www.bmj.com. 4 December 2003.

Larsen J, Andersen M, Bjerrum L, Kragstrup J, Gram LF. Insufficient use of lipid-lowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction. *J Cardiovascular Risk* 2003; 10: 61-4.

Llor C, Cots JM, Bjerrum L. Cincuenta años de penicilina en la faringo-amigdalitis. Por qué no administrarla ahora cada 12 horas? *Siete Dias Medicos* 2003; 567/26: 77-8.

Munck A, Damsgaard J, Hansen DG, Bjerrum L, Søndergaard J. The Nordic method for quality improvement in general practice. *Quality in Primary Care* 2003: 11: 73-8.

Nielsen JB, Gyrd-Hansen D, Kristiansen IS, Nexøe J. Impact of socio-demographic factors on willingness to pay for the reduction of a future health risk. *J Environmental Planning and Management* 2003; 46: 39-47.

Nielsen LM, Halgrener J, Hansen BL. Respiratorisk syncytialvirus-infektioner hos børn i almen praksis. *Ugeskr Læger* 2003; 165: 2747-9.

Norderhaug I, Dahl O, Hoisaeter OA, Heikkila R, Klepp O, Kristiansen IS et al. Brachytherapy for prostatic cancer: a systematic review of clinical and cost effectiveness. *Eur Urol* 2003; 44: 40-6.

Rasmussen C-H, Munck A, Kragstrup J, Haghfelt T. Patient delay from onset of chest pain suggesting acute coronary syndrome to hospital admission. *Scand Cardiovasc J* 2003; 37: 183-6.

Schroll H, Støvring H, Kragstrup J. Forskelle i praktiserende lægers anvendelse af International Classification for Primary Care-diagnoser. Inter- og intraobservatørvariationen. *Ugeskr Læger* 2003; 165: 4104-7.

Støvring H. New statistical methods for estimation of prevalence, incidence and mortality based on pharmacoepidemiological and other health-related databases. (Abstract). *Danish Medical Bulletin* 2003; 50: 99.

Støvring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. *The Lancet* 2003; 362: 537-8.

Søndergaard J, Andersen M, Støvring H, Kragstrup J. Mailed prescriber feedback in addition to a clinical guideline has no impact: a randomized, controlled trial. *Scand J Prim Health Care* 2003; 21: 47-51.

Wisløff TF, Kristiansen IS. Hvordan måle effect ved risikoreduksjoner? *Tidsskr Nor Lægeforen* 2003; 123: 3266.